Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: A randomized clinical trial

S. L. WALSH ; S. D. COMER ; M. R. LOFWALL ; B. VINCE ; N. LEVY-COOPERMAN ; D. KELSH ; M. A. COE ; J. D. JONES ; P. A. NUZZO ; F. TIBERG ; B. SHELDON ; S. KIM | 2017
Dans JAMA Psychiatry (Vol.74, n°9, September 2017) Article : Périodique

Importance: Buprenorphine is an efficacious, widely used treatment for opioid use disorder (OUD). Daily oral transmucosal formulations can be associated with misuse, diversion, and nonadherence; these limitations may be obviated by a sustained r[...]

Plus d'info

Ajouter à la sélection

Efficacy of continuing medical education to reduce the risk of buprenorphine diversion

M. R. LOFWALL ; M. J. WUNSCH ; P. A. NUZZO ; S. L. WALSH | 2011
Dans Journal of Substance Abuse Treatment (Vol.41, n°3, October 2011) Article : Périodique

As office-based opioid dependence treatment (OBOT) has grown in the United States, postmarketing surveillance data reveal increased reports of buprenorphine misuse and diversion, it is important that doctors understand buprenorphine clinical pha[...]

Plus d'info

Ajouter à la sélection

The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers

L. S. MIDDLETON ; P. A. NUZZO ; M. R. LOFWALL ; D. E. MOODY ; S. L. WALSH | 2011
Dans Addiction (Vol.106, n°8, August 2011) Article : Périodique

AIMS Sublingual buprenorphine and buprenorphine/naloxone are efficacious opioid dependence pharmacotherapies, but there are reports of their diversion and misuse by the intranasal route. The study objectives were to characterize and compare thei[...]

Plus d'info

Ajouter à la sélection